Regenxbio (FRA:RB0) FFO


FRA:RB0 Regenxbio Inc FRA:RB0
55 GF Score
Price €13.00
GF Value €12.40
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Regenxbio FFO?

FFO (Funds from operations) only applies to REITs.

FRA:RB0
55GF Score
Regenxbio Inc FRA:RB0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (FRA:RB0) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be overvalued. The current stock price of €13.00 is trading 4.8% above its estimated GF Value™ of €12.40. GuruFocus considers Regenxbio to be Fairly Valued.

Key valuation signals for FRA:RB0:

  • FFO:
  • GF Value™: €12.40 vs. price of €13.00 (4.8% above fair value)
  • GF Score™: 55/100 with 9 warning signs

No single metric tells the full story. See the FRA:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RGNX:USARB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
55GF Score

Get the complete analysis for FRA:RB0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00
Price
€12.40
GF Value